Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-29
Target enrollment:
Participant gender:
Summary
The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.
Phase:
PHASE1
Details
Lead Sponsor:
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Collaborators:
BioXcel Therapeutics Inc Congressionally Directed Medical Research Programs RTI International United States Department of Defense VA Connecticut Healthcare System Yale University